PRNEWSWIRE
WALTHAM, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient-targeted messaging for emerging multiple sclerosis oral agents will need to provide high-level information regarding the efficacy and preservation of quality of life and forego catchy and/or short taglines highlighting oral dosing. The knowledgeable multiple sclerosis patient population is likely to already be informed about oral dosing and will want information regarding efficacy and safety so that they can readily compare these new agents to the efficacy and safety of currently available agents.
Continue reading this article on emerging MS Oral Therapies, by clicking here.
For those reading this article on Facebook, please check with our blog - to leave comments or to see what others write in comments to our blog posted articles.
You may want to bookmark or save to your favorites, the link to our Blog so that you can check back as often as you would like.
If not registered to receive our weekly MS related e-newsletter, published each Thursday, then please click this link to register. It will not take more than 20 seconds to complete this process. - Thank you
0 comments:
Post a Comment